Clinical Trials Browser

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

31 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT03924466 2024-02-16

VUBAR

Phase 2 Unknown

55 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

95 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Phase 2 Unknown

362 enrolled

Breast

HER2-positive Metastatic Breast Cancer

NCT04824014 2024-02-06

4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Phase 2 Unknown

150 enrolled

Breast

ER+ Breast Cancer

NCT05496101 2024-02-05

CLI-FAR

Phase 2 Unknown

60 enrolled

Breast

Breast Cancer Female

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

49 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Phase 2 Unknown

30 enrolled

Breast

Luminal B/HER2-negative Breast Cancer

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase 2 Unknown

480 enrolled

Breast

Breast Neoplasms

NCT06151249 2023-11-30

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

Phase 2 Unknown

32 enrolled

Breast

Breast Neoplasms, Fatigue

NCT03906669 2023-11-22

WinPro

Phase 2 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06133088 2023-11-15

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Phase 2 Unknown

53 enrolled

Breast

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

NCT04267315 2023-10-16

Trigger Point Injections for Post-Mastectomy Pain Syndrome

Phase 2 Unknown

72 enrolled

Breast

Breast Neoplasms, Myofascial Pain Syndromes

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04883814 2023-09-28

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

Phase 2 Unknown

124 enrolled

Breast

Breast Neoplasms

NCT05800834 2023-09-28

MorphineGEL

Phase 2 Unknown

106 enrolled

BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Phase 2 Unknown

78 enrolled

Breast

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Phase 2 Unknown

46 enrolled

Breast

HER2 Positive Metastatic Breast Cancer

NCT03712956 2023-09-21

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Phase 2 Unknown

63 enrolled

Breast

Breast Neoplasms

NCT04165993 2023-09-21

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Phase 2 Unknown

68 enrolled

Breast

Breast Neoplasms

NCT05353361 2023-09-15

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Phase 2 Unknown

402 enrolled

Breast

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

123 enrolled

Breast

Breast Cancer Metastatic

NCT06000033 2023-08-21

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05967884 2023-08-01

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05969184 2023-08-01

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Phase 2 Unknown

94 enrolled

Breast

Breast Neoplasm Female

NCT05966441 2023-07-28

Role of Curcumin in Paclitaxel Induced PN

Phase 2 Unknown

80 enrolled

Breast

Breast Neoplasms

NCT05945368 2023-07-14

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

Phase 2 Unknown

78 enrolled

Breast

HER2-positive Breast Cancer

NCT02679040 2023-07-03

HIST-RIC

Phase 2 Unknown

101 enrolled

Breast

Breast Neoplasms

NCT04304352 2023-06-28

VEX

Phase 2 Unknown

162 enrolled

Breast

Advanced Breast Cancer

NCT05889728 2023-06-05

Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT05885776 2023-06-02

PYTHON

Phase 2 Unknown

48 enrolled

Breast

Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

65 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05880927 2023-05-30

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Phase 2 Unknown

150 enrolled

Breast

Breast Neoplasms

NCT05878678 2023-05-26

Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position

Phase 2 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Phase 2 Unknown

82 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04293276 2023-05-06

DAP-Her-01

Phase 2 Unknown

41 enrolled

Breast

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

Phase 2 Unknown

122 enrolled

Breast

Breast Neoplasms

NCT05808582 2023-04-14

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Phase 2 Unknown

60 enrolled

Breast

Hormone Receptor-positive Advanced Breast Cancer

NCT04733417 2023-04-13

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Phase 2 Unknown

35 enrolled

Breast

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2 Unknown

46 enrolled

Breast

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05806047 2023-04-10

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Phase 2 Unknown

23 enrolled

Breast

Hormone Receptor-positive Advanced Breast Cancer

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT00431704 2023-03-24

VinCaT

Phase 2 Unknown

39 enrolled

Breast

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma